Robert Berman, Chief Medical Officer at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 70,000 shares at $29.88 ($2.1M) on 2018-02-12, disclosed to the SEC on 2018-02-14.
Open-market sale of $2.1M BHVN by Chief Medical Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.88 | 2,364 | $71K | 3.3% |
| 2 | $29.88 | 2,364 | $71K | 3.3% |
| 3 | $29.88 | 9,456 | $283K | 13.3% |
| 4 | $29.88 | 9,456 | $283K | 13.3% |
| 5 | $30.69 | 18,544 | $569K | 26.7% |
| 6 | $30.69 | 18,544 |
| $569K |
| 26.7% |
| 7 | $30.69 | 4,636 | $142K | 6.7% |
| 8 | $30.69 | 4,636 | $142K | 6.7% |
| Total | $30.42 avg | 70,000 | $2.1M | 100% |
| Filing → |
| BHVN | SELL | 2020-06-22 | $9.3M | — | Filing → |
| BHVN | SELL | 2019-12-31 | $13.3M | — | Filing → |
| BHVN | BUY | 2019-06-28 | $106K | — | Filing → |